pirtobrutinib
eli lilly
['oval,(-approval)', 'cll']
at #eha2022, we re presenting results from the bruin phase 1b study of a highly selective, reversible (non-covalent) #btki in combination w/ a #bcl2 inhibitor +/- immunotherapy for patients w/ relapsed/refractory #cll. view presentation details here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK